[Market Focus] Samchundang Pharm, No. 1 in KOSDAQ Market Cap, Rises for 5 Consecutive Days...Hits Record High
Samchundang Pharm, which has taken the top spot in KOSDAQ market capitalization, continued its upward trend for the fifth consecutive day, reaching a new all-time high during intraday trading.
As of 9:45 a.m. on March 23, shares of Samchundang Pharm were trading at 943,000 won, up 36,000 won (3.97%) from the previous session. The stock hit a record high of 974,000 won during intraday trading. Over the past five consecutive trading days, Samchundang Pharm's share price surged from the 700,000 won range to over 900,000 won.
On March 20, the company overtook Ecopro to become the number one company by market capitalization on KOSDAQ for the first time. This was driven by a more than 14% rally following the announcement that it had completed the application for Phase 1 and 2 clinical trials of its oral insulin in Europe, securing the top market cap position.
Hot Picks Today
"Heading for 2 Million Won": The Company the Securities Industry Says Not to Doubt [Weekend Money]
- About 100 Trillion Won at Stake... "Samsung Strike Is an Unprecedented Opportunity" as Prices Surge 20% [Taiwan Chip Column]
- "Anyone Who Visited the Room Salon, Come Forward"… Gangnam Police Station Launches Full Staff Investigation After New Scandal
- "Envious of Korean Daily Life"...Foreign Tourists Line Up in Central Myeongdong from Early Morning [Reportage]
- Did Samsung and SK hynix Rise Too Much?... Foreign Assets Grow Despite Selling [Weekend Money]
Haejoo Wi, a researcher at Korea Investment & Securities, said, "The company achieved three momentum events in the first quarter alone. The announcement of the completion of the IND (Investigational New Drug) submission for the Phase 1 and 2 clinical trials of oral insulin in Europe marks the first achievement in more than a decade of research and development. Clinical trial results are expected to be available by the end of the year. If successful, this would bring the company closer to becoming the world's first developer of oral insulin, making it a potential game-changer in the market," he said.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.